CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)
Recruiting
N/A
Interventional Study
Multiple Myeloma (MM)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 60 (estimated)
- Sponsor
- Poitiers University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma plasma cells. These modified T lymphocytes are called CAR T cells (chimeric antigen receptor T cells). The long-term persistence of these modified lymphocytes, or CAR-BCMA, is…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient aged 18 and over
* Patient with Multiple Myeloma according to international recommendations,
* Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France.
Exclusion Criteria:
* Patients with severely impaired physical and/or…
Contacts